title: [Preliminary study on mechanism of therapeutic effect of Huganjiexian decoction on hepatic fibrosis].
abstract: OBJECTIVE
  To observe the effects of Huganjiexian decoction on rat hepatic fibrosis and the creation of cytokines.
  
  
  METHODS
  Rat hepatic fibrosis was induced by intraperitoneally injection of carbon tetrachloride. At the same time, these rats were treated with different dosages of Huganjiexian decoction. Sho-saiko-to compound treating group and Fufangbiejiarangan Tablets treating group were used as positive controls. After twelve weeks, all rats were executed. Histopathologic changes were observed after H.E and Masson stainings. The expression of collagen type I, collagen type III, TGF-beta 1 and PDGF-BB in liver were detected by immunohistochemical staining.
  
  
  RESULTS
  Compared with fibrotic group, hepatic fibrosis in decoction groups was significantly improved. In decoction groups, levels of collagen type I, collagen type III, TGFbeta1 and PDGF-BB were decreased, especially in the low-dose curcumin group. The TGF-beta 1 positive percentage were 7.56%+/-2.18%, 29.25%+/-7.84%, 13.54%+/-4.15%, 21.82%+/-6.64%, 20.06%+/-7.14%, 13.78%+/-4.35%, 12.75%+/-3.98% in liver tissues from normal group, model group, low, middle, high curcumin, Sho-saiko-to compound and Fufangbiejiarangan Tablets treating groups respectively (P less than 0.05); while the PDGF-BB positive percentage were 1.68%+/-0.41%, 11.70%+/-2.28%, 3.65%+/-0.76%, 5.24%+/-1.04%, 6.37%+/-1.12%, 4.16%+/-0.61%, 3.38%+/-0.56% in liver tissues from those groups respectively (P less than 0.05).
  
  
  CONCLUSIONS
  Huganjiexian decoction can improve rat hepatic fibrosis, possibly via inhibiting the expression of collagen type I, collagen type III, TGFbeta1 and PDGF-BB.
authors.affiliation: Department of Gastroenterology, Guangzhou Red Cross Hospital Affiliated to Medical College of Ji'nan University, Guangzhou 510220, China. shujc62@hotmail.com
authors.forename: Jian-Chang
authors.initials: JC
authors.lastname: Shu
authors.forename: Lian-Xiang
authors.initials: LX
authors.lastname: Chen
authors.forename: Liang
authors.initials: L
authors.lastname: Deng
authors.forename: Xia
authors.initials: X
authors.lastname: Lv
authors.forename: Ya-Jun
authors.initials: YJ
authors.lastname: He
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Zhu
authors.forename: Jing
authors.initials: J
authors.lastname: Fu
authors.forename: Guo-Rong
authors.initials: GR
authors.lastname: Ye
authors.forename: Hai-Hua
authors.initials: HH
authors.lastname: Zhou
mesh_terms: D000818:Animals; D000077214:Becaplermin; D024042:Collagen Type I / Q000378:metabolism; D024061:Collagen Type III / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008516:Medicine, Chinese Traditional; D008517:Phytotherapy; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D024042:Collagen Type I; D024061:Collagen Type III; D004365:Drugs, Chinese Herbal; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D053773:Transforming Growth Factor beta1; D000077214:Becaplermin